Table 1.
List of included studies.
| Nr | First author | Title | Journal | Year |
|---|---|---|---|---|
| 01 | Louapre C. | Clinical Characteristics and Outcomes in Patients with Coronavirus Disease 2019 and Multiple Sclerosis | JAMA Neurol. | Jul,2020 |
|
02 |
Oreja-Guevara C. | COVID-19 in cladribine-treated patients with Multiple Sclerosis | 8th Joint ACTRIMS-ECTRIMS Meeting | Sep,2020 |
| 03 | Hervás-García J. V. | Seroprevalence of SARS-CoV-2 in multiple sclerosis patients under immunomodulatory treatment in lleida (study emCOVID-19) | Mult Scler. | Dec,2020 |
| 04 | Salter A. | Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients with Multiple Sclerosis | JAMA Neurol. | Mar,2021 |
| 05 | Czarnowska A. | Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience | Neurol Neurochir Pol. | Apr,2021 |
| 06 | Sormani M. P. | Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis | Annals of Neurology | Jan,2021 |
| 07 | Arrambide G. | SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry | Neurol Neuroimmunol Neuroinflamm. | Jun,2021 |
|
08 |
Spelman T. | Increased rate of hospitalization for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry | Mult Scler. | Jul,2021 |
| 09 | Drulovic J. | Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies | Mult Scler Relat Disord. | Jul,2021 |
| 10 | Fragoso Y. D | Coronavirus disease 2019 in Latin American patients with multiple sclerosis | Mult Scler Relat Disord. | Jul,2021 |
| 11 | Bsteh G. | COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry | Plos one | Jul,2021 |
| 12 | Perez A. C. | COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study | Mult Scler Relat Disord. | Aug,2021 |
| 13 | Yavorskaya V. | Clinical Outcomes in Patients With COVID-19 During Two Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis: An Update |
AAN 2022 | Apr,2022 |